Revance Therapeutics, Inc. (NASDAQ:RVNC) CEO L Daniel Browne sold 7,662 shares of the business’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $26.16, for a total value of $200,437.92. Following the completion of the transaction, the chief executive officer now directly owns 140,788 shares in the company, valued at approximately $3,683,014.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

L Daniel Browne also recently made the following trade(s):

  • On Wednesday, September 20th, L Daniel Browne sold 7,600 shares of Revance Therapeutics stock. The stock was sold at an average price of $23.58, for a total value of $179,208.00.
  • On Wednesday, August 23rd, L Daniel Browne sold 22,800 shares of Revance Therapeutics stock. The stock was sold at an average price of $22.76, for a total value of $518,928.00.

Shares of Revance Therapeutics, Inc. (NASDAQ RVNC) traded down 1.35% on Friday, hitting $25.50. The stock had a trading volume of 119,551 shares. The stock’s market cap is $785.88 million. Revance Therapeutics, Inc. has a 12 month low of $12.35 and a 12 month high of $28.75. The stock has a 50 day moving average of $25.96 and a 200-day moving average of $23.68.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.93) by $0.03. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. Revance Therapeutics had a negative return on equity of 55.21% and a negative net margin of 32,936.67%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.88) EPS. Equities research analysts anticipate that Revance Therapeutics, Inc. will post ($3.61) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Revance Therapeutics, Inc. (RVNC) CEO Sells $200,437.92 in Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/20/revance-therapeutics-inc-rvnc-ceo-sells-200437-92-in-stock.html.

Several institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its holdings in shares of Revance Therapeutics by 4.8% in the second quarter. JPMorgan Chase & Co. now owns 3,626,603 shares of the biopharmaceutical company’s stock worth $95,743,000 after acquiring an additional 166,759 shares during the period. Franklin Resources Inc. grew its holdings in shares of Revance Therapeutics by 13.1% in the second quarter. Franklin Resources Inc. now owns 3,375,238 shares of the biopharmaceutical company’s stock worth $89,106,000 after acquiring an additional 391,638 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Revance Therapeutics by 14.4% in the second quarter. Bank of New York Mellon Corp now owns 2,079,562 shares of the biopharmaceutical company’s stock worth $54,901,000 after acquiring an additional 261,764 shares during the period. Vanguard Group Inc. grew its holdings in shares of Revance Therapeutics by 7.3% in the second quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock worth $24,595,000 after acquiring an additional 63,505 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Revance Therapeutics by 34.7% in the first quarter. Goldman Sachs Group Inc. now owns 548,650 shares of the biopharmaceutical company’s stock worth $11,412,000 after acquiring an additional 141,400 shares during the period. 89.32% of the stock is owned by institutional investors.

Several research firms have weighed in on RVNC. BidaskClub cut Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Zacks Investment Research cut Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. Piper Jaffray Companies set a $28.00 price objective on Revance Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 26th. JMP Securities began coverage on Revance Therapeutics in a research report on Tuesday, August 22nd. They issued an “outperform” rating and a $34.00 price objective on the stock. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price objective on shares of Revance Therapeutics in a research report on Tuesday, September 26th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Revance Therapeutics presently has an average rating of “Buy” and a consensus price target of $35.20.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Insider Buying and Selling by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.